Justifying a multidisciplinary high-intensity hepatitis C clinic by using decision analysis

American Journal of Health-System Pharmacy

Volumn 59, Issue 9, 2002, Pages 867-871

  Dolder, Nicole M ^a   Wilhardt, Michelle S ^a   Morreale, Anthony P ^a  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; LIVER ENZYME; RIBAVIRIN; VIRUS RNA;

ARTICLE; GENOTYPE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; METHODOLOGY; PATIENT CARE; PATIENT EDUCATION; PATIENT SELECTION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SOLDIER; TREATMENT INDICATION;

EID: 0036569581     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.9.867     Document Type: Article

References (16)

1. National hepatitis C surveillance day in the Department of Veterans Affairs
2. Standards of treatment in chronic hepatitis C
3. Hepatitis C: Natural history, diagnosis, and management
4. Estimates of the cost-effectiveness of a single course of interferon alpha-2b in patients with histologically mild chronic hepatitis C
5. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C
6. Guidelines: The pharmacologic management of chronic hepatitis C virus infection
7. Decision analysis and pharmacoeconomic evaluations
8. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
9. Lessons from medicine and nursing for pharmacist-patient communication
10. Consensus among consensus conferences on management of hepatitis C: What we knew then and are still sure about, what we are newly sure about, and what we still need to know
11. Improving outcomes of community-dwelling older patients with diabetes through pharmacist counseling
12. Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs
13. Protocol for pharmacist management of antineoplastic drug-induced adverse effects in out-patients
14. Physician-pharmacist teams help in control of blood-pressure
15. Development and evaluation of a pharmacist-managed asthma education clinic